Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics

Area of Science:

• Biotechnology
• Protein Chemistry
• Pharmaceutical Sciences

Background:

• Monoclonal antibodies (mAbs) are crucial therapeutics for diseases like cancer.
• mAb instability, particularly aggregation, poses significant commercialization challenges.
• Aggregation can alter protein structure, trigger immune responses, and increase production costs.

Purpose of the Study:

• To investigate the rate and mechanism of higher-order mAb oligomer formation.
• To understand the impact of environmental conditions (buffer, temperature, pH, salt) on mAb aggregation.
• To identify the best kinetic model for mAb aggregation to guide process optimization.

Main Methods:

• Size exclusion chromatography (SEC) for characterizing mAb aggregates.
• Experimental manipulation of environmental conditions (buffer type, temperature, pH, salt concentration).
• Application and comparison of Extended Lumry-Eyring (ELE), LENP, and Finke-Watzky (F-W) models.

Main Results:

• Characterization of mAb aggregation kinetics under diverse conditions.
• Evaluation of the suitability of ELE, LENP, and F-W models for mAb aggregation data.
• Identification of critical parameters influencing mAb aggregation rates and mechanisms.

Conclusions:

• Understanding mAb aggregation mechanisms is vital for biopharmaceutical development.
• The findings will aid in preventing product aggregation during manufacturing and storage.
• Selecting the appropriate kinetic model can improve prediction and control of mAb stability.